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ReviewThe ligand-stimulated epidermal growth factor receptor
(EGFR) has been extensively studied in the analysis of
molecular mechanisms regulating endocytic traffic and
the role of that traffic in signal transduction. Although
such studies have largely focused on mitogenic signal-
ing and dysregulated traffic in tumorigenesis, there is
growing interest in the potential role of EGFR traffic
in cell survival and the consequent response to
cancer therapy. Here we review recent advances in our
understanding of molecular mechanisms regulating
ligand-stimulated EGFR activation, internalization, and
post-endocytic sorting. The role of EGFR overexpression/
mutation and new modulators of EGFR traffic in cancer
and the response to cancer therapeutics are also dis-
cussed. Finally, we speculate on the relationship between
EGFR traffic and cell survival.
Overview of EGFR signaling regulation
EGFR plays key roles in essential cellular functions in-
cluding proliferation and migration. However, its aberrant
activity in the pathogenesis of human cancers underlies
our need to understand the complex regulation of EGFR
activity and downstream signaling events. Widely consid-
ered as the prototypic receptor tyrosine kinase (RTK),
EGFR endocytic traffic and regulation has been the subject
of considerable scrutiny but although enormous advances
have been made our understanding remains incomplete.
The prevailing consensus has historically viewed endo-
cytic transport of activated RTKs as a means of signal
attenuation. This view is supported by the enhanced EGF-
stimulated mitogenic signaling and proliferation in cells
expressing either a non-internalizing mutant EGFR [1] or
a dynamin mutant that prevents clathrin-mediated endo-
cytosis [2]. Moreover, EGF-stimulated MAPK (mitogen-
activated protein kinase) signaling was found to occur
primarily at the plasma membrane, independently of
dynamin activity [3]. However, a more complex picture
of multifaceted, spatial, and temporal regulation is emerg-
ing. EGFR can be activated by ligand-independent mech-
anisms as well as by multiple ligands, often with differing0962-8924/$ – see front matter
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majority of EGFR signaling is believed to occur at the
plasma membrane [3,4], activated EGFR-mediated sig-
nals can continue from endosomes, suggesting distinct
signaling pathways exist that actively require EGFR en-
docytosis [2,5].
This review addresses the regulation of EGFR endocytic
trafficking and the consequences of this regulation for the
spatiotemporal control of signaling and cell fate in normal
conditions, as well as in tumorigenesis and the response to
cancer therapy.
Ligand-stimulated EGFR activation
To date eight EGFR ligands have been described. Crystal-
lography studies have revealed that ligand-mediated
EGFR activation is achieved by a conformational change
in the extracellular domain of the receptor upon ligand
binding, resulting in receptor dimerization and internali-
zation [6]. Unliganded EGFR can also be internalized but
at a 10-fold slower rate than EGF-stimulated receptor [7],
but the dimerization and activation states of these recep-
tors are unclear. Crucial to RTK activation is the formation
of an asymmetric dimer of kinase domains [8]. Recent data
have implicated cytohesins, guanine nucleotide exchange
factors for ADP-ribosylation factors, in this process [9], and
cytohesin-mediated conformational modification of EGF-
bound receptor dimers from the cytoplasmic side is
reported to increase RTK activity. The EGFR has also
been shown to fluctuate between monomer and dimer
states, even in the absence of ligand, but ligand binding
was found to promote dimerization and be required for
signaling [10]. Consistent with this, it has recently been
proposed that EGFR autoinhibition in the absence of EGF
exists when the receptor is on the plasma membrane, and
is relieved by interaction between transmembrane helices
on ligand binding or under conditions of very high receptor
expression [11]. Other factors implicated in the regulation
of EGFR activation include association with flotillins at
the plasma membrane [12] and interaction with Ca2+/
calmodulin complexes via the calmodulin-binding domain
at the cytosolic juxtamembrane region of the EGFR [13].
Active EGFR dimers undergo autophosphorylation of tyro-
sine residues in the cytoplasmic tail of the receptor. Con-
sequently, phosphotyrosine-binding proteins are recruited,
activating multiple signal transduction pathways, includ-
ing the MAPK signaling cascade, the phosphoinositide-3-
kinase (PI3K) pathway, which recruits Akt/PKB to the
plasma membrane, and the phospholipase Cg pathway,
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Figure 1. EGF receptor (EGFR) trafficking pathways and associated outcomes. Activated cell-surface EGFRs are internalized and sorted at the early endosome. The fate of
the receptor has important consequences for biological cell outputs, with the recycling pathway favoring cell proliferation (depicted green), although the degradative
pathway via ESCRT (endosomal sorting complex required for transport)-mediated sorting within multivesicular bodies (MVBs)/lysosomes correlates with normal cellular
homeostasis (depicted in blue). Atypical trafficking pathways to the nucleus and mitochondria have also been described and are proposed to favor survival, but the
transport mechanisms are not well established. Exposure to stress leads to the removal of the receptor from the cell surface, and this has been proposed to potentiate cell
death (depicted in red). Conversely, stress-activated receptor might also be recycled, thereby promoting cell survival and/or proliferation.
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kinase C (PKC) activation (reviewed in [14]).
Ligand-stimulated EGFR endocytosis: a positive and
negative regulator of signaling
Signaling from activated EGFR, including the MAPK sig-
naling cascade as well as PI3K activation, occurs mostly
from the plasma membrane [3,4], and endocytosis is
thought to initiate termination of the signal. However,
internalization of activated EGFR also enables specific
signaling pathways from intracellular sites, and endocytic
trafficking of EGFRs is required for optimal activation of a
subset of signal transducers [2].
The clathrin adaptor protein complex AP2
Some controversy exists over the mechanisms of EGFR
endocytosis. The involvement of the clathrin adaptor pro-
tein complex AP2 in EGFR endocytosis has been the
subject of debate following conflicting reports of the effects
of small interfering RNA (siRNA)-mediated depletion of
AP2 on EGFR endocytosis [15,16]. Interaction between
EGFR and the m2 subunit of AP2 has been demonstrated
(reviewed in [17]). Moreover, the AP2 b2 subunit becomes
tyrosine-phosphorylated upon EGF stimulation, a process
dependent on the dileucine motif in the EGFR carboxyl
terminus [18]. Mutation of this motif, however, did not
affect EGFR endocytosis, but targeting of the receptor fordegradation was disrupted, suggesting that either the
EGFR dileucine motif or AP2 b2 phosphorylation might
facilitate the recruitment of downstream sorting machin-
ery. Taken together, these studies suggest that although
AP2 is not an absolute requirement of clathrin-mediated
endocytosis (CME) of the EGFR its interaction with EGFR
and role in recruiting other components of the endocytic
machinery can facilitate endocytosis and the passage of
activated EGFR through the endocytic pathway.
Grb2 and EGFR ubiquitination
Another EGFR-binding adaptor protein is growth factor
receptor-bound protein 2 (Grb2), which binds activated
EGFR through its Src homology 2 (SH2) domain [19]. This
interaction mediates apparently opposing effects on sig-
naling: downregulation through internalization and ubi-
quitination-targeted degradation but also activation of
signaling cascades through interaction of Grb2 SH3
domains with the Ras guanine exchange factor, son of
sevenless homolog (SOS) [20]. Grb2 recruits the E3 ubi-
quitin ligase Cbl, resulting in monomeric and polymeric
ubiquitination on lysine residues in the kinase domain of
the EGFR [21] as well as modification with monomers of
the ubiquitin-like molecule NEDD8 (neural precursor cell
expressed developmentally downregulated protein 8) [22].
Interaction with the GTP-bound active form of Ras results
in Raf activation and initiation of the MAPK signaling27
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activation is also mediated by interaction of Grb2 and Gab1
[23], and functions in a positive feedback loop, producing
PI3,4,5P3, which targets Gab1 to the plasma membrane in
response to EGF stimulation, where direct Gab1–EGFR
interaction potentiates MAPK activation [24].
EGFR ubiquitination is recognized by ubiquitin-binding
proteins of the clathrin coat, including the AP2-interacting
proteins epsin1 and Eps15. Although ubiquitination has
been reported to facilitate recruitment of activated EGFR
to clathrin-coated pits and promote CME [25,26], a recep-
tor lacking 15 lysine residues in the kinase domain is
negligibly ubiquitinated but is internalized normally
[27]. Moreover, EGFR CME was largely unaffected by
epsin1 or Eps15 depletion [28,29], although impaired in-
ternalization because of epsin1 depletion was also reported
[30]. The extent of the contribution of ubiquitination and
ubiquitination-dependent effectors (such as epsin and
Eps15) to EGFR internalization may depend on cell type
and physiological conditions. A recent study, mutating 21
lysine residues, three of which were found to be acetylated,
resulted in impaired internalization [1], raising the in-
triguing possibility that acetylation might be required
for EGFR dimerization, similarly to STAT3 [31] and the
prolactin receptor. Dimerization is crucial for ligand-stim-
ulated EGFR autophosphorylation, activation, and inter-
nalization, with the exception of constitutively active
mutant receptors (see ‘EGFR oncogenic mutations’, below).
Interestingly the dimerization state of EGFR activated
ligand-independently has not yet been established. Using
multiple EGFR mutations deficient in ubiquitination, acet-
ylation, and interaction with AP-2 and Grb2, Goh et al. [1]
concluded that regulation of CME of the EGFR is complex,
involving a combination of all of the above factors func-
tioning both redundantly and cooperatively.
Clathrin-independent EGFR endocytosis
CME offers a rapid internalization pathway, but slower
clathrin-independent mechanisms have also been reported,
and ligand concentration is thought to be important in
directing receptor passage through the endocytic pathway.
High EGF concentrations (20 ng/ml) were found to promote
clathrin-independent endocytosis (CIE) [32] in an epsin and
eps15-dependent manner [33], possibly due to saturation of
the clathrin-mediated pathway. Surprisingly, this study
found that CME promoted EGFR recycling with prolonged
signaling as a consequence. Consistent with this, Dynamin2
mutants were found to reduce CIE of EGFR without affect-
ing uptake of transferrin receptor, resulting in reduced
EGFR degradation [34]. Recently a Grb2/Cbl-dependent
ubiquitin threshold was described that correlates with
EGFR CIE and downregulation of signal transduction, al-
though exactly how ubiquitination and CIE are coupled
remains unclear [35]. It should be noted that CIE of EGFR
remains controversial because, in separate studies,
clathrin depletion was found to inhibit EGFR endocytosis
even at high ligand concentrations, with the disparity being
attributed to the relative efficiencies of clathrin depletion
[36,37]. The type of activating ligand itself is also important.
Receptor activation by different ligands, EGF or transform-
ing growth factor (TGF-a), resulted in CME alone whereas28the most potent activators of EGFR, heparin-binding EGF-
like growth factor (HB-EGF) and betacellulin (BTC), stimu-
lated both clathrin-mediated and clathrin-independent
mechanisms [37]. The authors suggested that, although this
could be due to more efficient recruitment of residual cla-
thrin following this potent activation in clathrin-depleted
cells, an alternative as yet unidentified internalization
pathway might be employed under these conditions. Pro-
posed mechanisms of CIE include uptake via caveolae [38] or
via macropinocytosis, as observed in response to EGF stim-
ulation in A-431 cells [39], or in response to antibody binding
in porcine aortic endothelial cells [40]. Thus, a growing body
of evidence is emerging in support of a clathrin-independent,
dynamin2-dependent mechanism of internalization of
EGFR that may operate under particular physiological
conditions, perhaps involving saturation of the clathrin
machinery or a cellular response to potent RTK activation
(by ligand type or concentration), resulting in increased
traffic along the degradative pathway to maintain signal
homeostasis.
Post-endocytic EGFR sorting
Two major destinations exist for EGFR trafficking from
early endosomes: recycling to the cell surface or lysosomal
degradation. A delicate equilibrium between these two
pathways balances continued signaling both from endo-
somes and recycled EGFR at the cell surface against signal
attenuation in the degradative pathway. Furthermore,
subcompartmentalization of signaling has been shown to
occur within the endocytic pathway. A subpopulation of
early endosomes has been described that are positive for
the Rab5 effector APPL1, which was found to regulate AKT
activity from early endosomes [41]. Moreover, the Regula-
tor complex, comprising LAMTOR-1, -2, and -3, which
interacts with MEK1/ERK1, regulates continued EGF-
dependent MAPK signaling from late endosomes and lyso-
somes, and promotes in vivo proliferation [42].
Receptor ubiquitination and ESCRT (endosomal sorting
complex required for transport)-mediated sorting within
multivesicular bodies (MVBs)
As well as being recognized by components of the endo-
cytic machinery at the plasma membrane, receptor ubi-
quitination is crucial to sorting activated EGFR at the
endosome ([43] for review). The ESCRT machinery sorts
ubiquitinated receptor onto the intraluminal vesicles
(ILVs) of maturing endosomes, thereby physically remov-
ing the active kinase domain from cytosolic substrates as
well as targeting the ubiquitinated receptor for lysosomal
degradation. Ubiquitinated receptors are recognized by
several ubiquitin interacting motif (UIM)-containing pro-
teins including the Rab5 exchange factor, Rabex-5 [44],
the ESCRT-0 component, hepatocyte growth-factor regu-
lated tyrosine kinase substrate (Hrs), and the ESCRT-I
component, tumor susceptibility gene 101 (Tsg101). In-
deed, EGFR ubiquitination is required for its interaction
with Hrs and efficient lysosomal targeting [45]. Hrs in-
teraction with the ESCRT-I component, Tsg101, pro-
motes recruitment of subsequent ESCRT complexes,
with ESCRT-III-dependent scission completing ILV
biogenesis. Before sorting onto ILVs, the ubiquitin is
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recycled to maintain the free ubiquitin pool. The DUBs
AMSH (associated molecule with the SH3 domain of
STAM) [46] and UBPY (ubiquitin isopeptidase Y/ubiqui-
tin-specific protease 8) [47], bind both the ESCRT-0 com-
ponent STAM (signal transducing adaptor molecule) and
ESCRT-III complex members [48], and are implicated in
regulating EGFR sorting onto the degradative pathway.
By contrast, Cezanne-1, a DUB that is overexpressed in
breast cancer, has recently been reported to prevent
EGFR degradation, resulting in enhanced oncogenic
signaling [49]. As an additional level of EGF RTK regu-
lation, endocytosed EGFR can be subject to direct dephos-
phorylation by protein tyrosine phosphatases (PTPs)
([50] for review), including the endoplasmic reticulum
(ER)-localized PTP1B which interacts with endocytosed
EGFR at membrane contact sites between the ER and
endosomes [51] (Box 1). The type 1g phosphatidylinositol
phosphate kinase variant i5 (PIPK1gi5) that phosphor-
ylates phosphatidylinositol-4-phosphate to produce phos-
phatidylinositol-4,5-bisphosphate (PI4,5P2), was recently
shown, together with its binding partner SNX5 (sortingBox 1. PTP1B: paradoxical roles in EGFR downregulation
and tumorigenesis
The protein tyrosine phosphatase, PTP1B, is tyrosine phosphory-
lated (Y66) by activated EGFR, resulting in a threefold increase in its
catalytic activity [99]. Moreover, ER-localized PTP1B has also been
shown to both interact with and dephosphorylate activated
endocytosed EGFR [100]. How this ER-localized phosphatase might
interact with activated EGFR on the endocytic pathway was resolved
by the identification of membrane contact sites (MCSs), regions of
close membrane apposition (<20 nm), between the ER and endo-
somes [51]. In addition to its role in EGFR dephosphorylation, PTP1B
activity also promotes the formation of ILVs and the lysosomal
targeting of activated EGFR, likely via its dephosphorylation of the
ESCRT-0 components Hrs and STAM [51,101]. Thus PTP1B activity is
able to modulate both endocytic cargo and machinery, with
downregulation of RTK signaling and therefore suppression of
tumor development being the predicted outcome of its activity.
Consistent with a tumor-suppressor role, genetic ablation of
PTP1B in p53-null mice resulted in accelerated lymphomagenesis
[102], and increased ligand-stimulated phosphorylation of the EGFR
was observed in PTP1B-null mouse fibroblasts [103]. Surprisingly,
however, PTP1B knockout mice do not develop tumors and,
although EGF-stimulated EGFR phosphorylation is increased, cell
proliferation is not [104]. Indeed, PTP1B loss was found to diminish
Ras activity through increased p62Dok phosphorylation [105],
suggesting a potentially oncogenic role for PTP1B. This was
confirmed when PTP1B activity was shown to promote ErbB2-
dependent mammary tumorigenesis [104,106]. Activation of c-Src
by PTP1B-mediated dephosphorylation of the inhibitory Y530 site
[107] could account for tumorigenic effects of PTP1B activity [104].
Src kinase can interact with and phosphorylate RTKs including
EGFR, and regulate proliferation through the Erk/MAP kinase
pathway [108]; overexpression or increased activation of Src is
found in several cancers including breast and colon cancers and is
frequently linked with high EGFR levels [109]. In addition, PTP1B
has recently been shown to promote the progression of prostate
cancer [110], adding further evidence of a role for PTP1B activity in
tumorigenesis and making it an attractive target for cancer therapy.
PTP1B plays a pivotal role in the regulation of insulin and leptin, and
is a target for diabetes therapies; small-molecule inhibitors of PTP1B
have been developed which could have potential application to
cancer therapy. However, further understanding of the mechanism
and regulation of PTP1B activity is necessary before it can be
exploited for therapeutic benefit.nexin 5), to play a role in regulating the sorting of
activated receptor onto ILVs [52]. Phosphoinositides play
central roles in CME at the plasma membrane [53,54],
but this study suggests additional functions for PI4,5P2
at the endosome. Loss of PIPK1gi5 or SNX5 blocked
EGFR sorting onto ILVs owing to increased Hrs ubiqui-
tination, previously shown to prevent Hrs–EGFR inter-
action, resulting in enhanced and prolonged signaling.
Regulation of EGFR recycling
The importance of ubiquitination in targeting activated
EGFRs for degradation is established; negligibly-ubiquiti-
nated EGFR mutants that evade the degradative pathway
were recently shown to be recycled to the plasma mem-
brane [45]. Thus perhaps recycling might serve as a default
pathway. However, the identification of several effectors of
EGFR recycling suggests a more active and regulated
process. Receptor recycling can occur either by the direct
Rab4- and Rab35-regulated route to the plasma membrane
or by a Rab11-dependent route via the perinuclear endo-
cytic recycling compartment (ERC). The calcium-modulat-
ing cyclophilin ligand (CAML) was reported to associate
with the activated EGFR kinase domain, promoting EGF-
stimulated receptor recycling [55]. Recently Eps15S, a
short isoform of Eps15, was identified that targets endo-
cytosed EGFR for recycling through the Rab11-positive
ERC [56]. In addition, the adaptor protein Odin, a target
of Src kinase activity [57], was found to promote EGF-
stimulated receptor recycling [58]. Although increased
recycling is predicted to prolong signaling, Odin has also
been described as a negative regulator of EGFR signaling
[59]. This apparent contradiction is yet to be explained but
may involve downstream Odin-mediated suppression of
signaling pathways.
Other factors affecting the passage of EGFR through
the endocytic pathway include Hrs phosphorylation and
AMSH-mediated deubiquitination of the receptor, and
loss of Hrs phosphorylation and AMSH activity are asso-
ciated with increased EGFR recycling [46]. The activating
ligand can also direct EGFR traffic, depending on the pH-
dependent stability of ligand–receptor interactions [60].
EGF binding, for example, remains stable at the reduced
pH in endosomes, allowing targeting to the degradative
pathway, whereas TGF-a dissociates at endosomal pH.
The consequent deubiquitination upon dissociation allows
the receptor to escape lysosomal targeting, and instead
be recycled to the plasma membrane, consistent with the
increased mitogenic effects of TGF-a [61]. Furthermore,
the EGFR dimerization partners can also dictate its fate.
As well as forming homodimers, EGFRs can form hetero-
dimers with other EGFR family members. Whereas on
EGF stimulation EGFR homodimers are sorted for degra-
dation, heterodimers fail to recruit Cbl, thereby evading
degradation and are instead recycled. For example,
EGFR/ERBB2 heterodimers, that are overexpressed in
many human tumors, are internalized at a slower rate,
with increased recycling to the cell surface [62].
Alternative fates for endocytosed EGFR
Sorting of activated EGFR for lysosomal degradation (and
therefore attenuation of signaling) or recycling to the29
Box 2. Potential mechanisms for nuclear translocation of
endocytosed EGFR
Potential mechanisms for the translocation of full-length EGFR to
the nucleoplasm are beginning to emerge. The recovery of EGFR in
ER fractions following prolonged EGF stimulation [111] was the first
indication that a subset of EGFR might follow the retrograde
pathway from the endosomes to the ER that is taken by some
endocytosed toxins.
The retromer protein complex participates in the retrieval of
proteins from the endosome to the Golgi, and binds phosphatidyli-
nositol 3,5-bisphosphate (PI3,5P2), a lipid synthesized by PIKfyve.
PIKfyve dysfunction impairs endosome–Golgi transport, and a role for
this pathway in nuclear transport is supported by the inhibition of
ligand-stimulated EGFR trafficking to the nucleus in human bladder
cancer cells in which PIKfyve function is impaired [112]. The COP1
coat protein complex mediates retrograde transport through the
Golgi and to the ER, and depletion of COP1 was also recently shown
to inhibit EGF-stimulated transport of EGFR to the nucleus [113]. EGF-
stimulated retrograde transport of EGFR to the Golgi and subsequent
translocation to the nucleus were also reported to depend on a
membrane fusion event driven by the SNARE protein syntaxin 6 and
on dynein-dependent transport along microtubules [114].
A role for the Sec61 translocon, Sec61b, in EGFR translocation
from the ER to the cytoplasm has been proposed, with nuclear
translocation of EGF-stimulated EGFR being inhibited by depletion
of Sec61b [111]. Whether Sec61b is also involved in EGFR nuclear
translocation following ligand-independent stimulation is unknown,
and how the EGFR is recognized by this machinery and the
molecular detail of the retrotranslocation remain unclear.
Membrane extraction of EGFR at the ER implies that EGFR must
pass through the cytosol before nuclear import. The hydrophobic
transmembrane domain of the EGFR suggests the involvement of
molecular chaperones, but how the retrotranslocated EGFR escapes
proteasomal degradation has yet to be demonstrated. A way to
avoid the conundrum presented by soluble EGFR in the cytoplasm is
suggested by a recent study reporting the presence of Sec61 and
EGFR on the inner nuclear membrane [115]. Entry into the nucleus
has been reported to involve association of the nuclear localization
sequence of EGFR with importins [116], proteins required for the
import of macromolecules through the nuclear pore complex, but
the mechanism regulating this transport remains unclear.
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fundamental to the regulation of EGFR signaling. Howev-
er, alternative fates for activated EGFRs are emerging,
including traffic to both the nucleus and the mitochondria.
Nuclear EGFR, that is reported to depend on the nuclear
localization sequence within the EGFR juxtamembrane
region that interacts with importin-b, has been proposed
to act as a transcriptional regulator and modulator of DNA
repair through interaction with DNA-dependent protein
kinase (DNA-PK). Proposed mechanisms of nuclear trans-
location are further detailed in Box 2 and reviewed in [63].
There is, however, a large pool of literature analyzing
EGFR trafficking that does not report EGFR trans-
port to the nucleus, and the exact mechanisms of nuclear
translocation remain controversial. EGFR transport to the
mitochondria, both constitutive and in response to a range
of stimuli, has also been reported, although the role of CME
is unclear, and both CME-dependent [64] and endocytosis-
independent mechanisms [65] have been reported. Mito-
chondrial EGFR was found to directly phosphorylate
cytochrome c oxidase subunit II (CoxII), involved in regu-
lating apoptosis, in a c-Src-dependent manner, with
reduced Cox activity and cellular ATP being reported
[64], and a role in drug resistance has further been suggested30[66]. However, the mechanism of translocation to the mito-
chondria and indeed the function of mitochondrial EGFR
remain to be fully defined.
Thus, in addition to the comparatively well-studied
recycling and degradative trafficking pathways of endocy-
tosed EGFR, alternative fates for the EGFR, including
translocation to the nucleus (Box 2) and mitochondria,
have been reported, and further studies will be necessary
to elucidate the nature and regulation of the transport
mechanisms involved.
EGFR trafficking and cancer
Abnormal expression and dysregulated intracellular traf-
ficking of the EGFR family of RTKs play important and
well-recognized roles in oncogenesis. Mutations of EGFR
have been identified in several types of cancer [67–69], and
the EGFR is the target for an expanding class of anticancer
therapies (reviewed in [70]). Trafficking defects resulting
in mislocalization and poor downregulation of the EGFR
are associated with enhanced signaling [71], which can
lead to the development of cancer [72]. Here we describe
the different mechanisms by which modulations in EGFR
trafficking and function can lead to oncogenesis or alter the
outcome of antineoplastic therapies.
EGFR oncogenic mutations: trafficking defects
Overexpression and particular oncogenic mutations of
EGFR lead to spontaneous dimerization of the receptor,
resulting in receptor activation [73]. Two main types of
mutant EGFRs have been identified in tumorigenesis, both
of which are constitutively active: truncated EGFR
mutants and those harboring mutations in the kinase
domain [74]. A range of constitutively-active oncogenic
EGFR mutants found in non-small cell lung cancer
(NSCLC) traffic into the ERC, allowing them to engage
in a preferential interaction with Src, a crucial partner for
EGFR-mediated oncogenesis [75]. Synergy between Src
and EGFR also occurs because these two kinases traffic
together, and their colocalization promotes EGFR-mediated
signaling [76]. Interestingly, the NSCLC-associated EGFR
mutants appear to be impaired in their interaction with Cbl,
resulting in their defective ubiquitination and degradation,
contributing to their prolonged signaling [77]. However, the
most common EGFR variant in glioblastoma, EGFR type
VIII, which harbors a deletion of 267 amino acids in the
extracellular domain – leading to a receptor that is unable to
bind ligand but is constitutively active [78] – is downregu-
lated after Cbl-mediated ubiquitination [79].
Role of oncogenes in the modulation of EGFR trafficking
Several oncogenes have been proposed to exert their action
by affecting EGFR trafficking. One such oncogene, the Rho
GTPase guanine nucleotide exchange factor Vav2, known
to regulate cell adhesion, motility, spreading, and prolifer-
ation in response to growth factor signaling, has been
shown to delay EGFR internalization and degradation,
and enhance EGFR, ERK, and Akt phosphorylation [80].
Another oncogene, activated Cdc42-associated Kinase
ACK1, is a non-RTK that can integrate signals from nu-
merous interacting partners, including Cdc42 and EGFR
[81]. ACK1 interacts with ubiquitinated EGFR to facilitate
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ylation of the Arp2/3 regulatory protein, cortactin, poten-
tially providing a link between Arp2/3-based actin
dynamics and EGFR traffic towards degradation [82]. A
single somatic mutation in ACK1 that abrogates ubiquitin
binding can stabilize the EGFR at the plasma membrane
[83], thereby prolonging mitogenic signaling after EGF
stimulation and making some cancers resistant to EGFR
kinase inhibitors such as gefitinib.
Another example of the importance of trafficking regula-
tion in tumorigenesis is the interaction between the tumor
suppressors PTEN (phosphatase and tensin homolog) and
SPRY2 (sprouty homolog 2). Reduced SPRY2 expression
causes hyperactivation of PI3K/AKT signaling in a
PTEN-dependent manner, resulting in increased cell pro-
liferation and invasion in prostate cancer [84]. The conse-
quent positive feedback results in increased EGFR
internalization and sustained signaling at the early endo-
some, in a mechanism involving activation of the stress-
inducible p38 MAPK by PI3K. As previously described
[85,86], activated p38 facilitates clathrin-mediated EGFR
internalization and evasion of degradation, and this allows
the sustained signaling observed at early endosomes.
The examples above illustrate the conflicting role of
EGFR traffic in signaling, with endocytosis resulting in
either positive or negative effects on signaling and tumori-
genesis, which is most likely due to complex interactions
between EGFR and its downstream effectors.
Anti-EGFR targeting drugs and combination therapies
Chemoradiotherapy, the combined treatment with two
DNA-damaging agents, namely ionizing radiation and
an alkylating agent such as cisplatin, is the standard
choice of treatment for many cancers. Applying a combina-
tion of X-rays or chemotherapy and EGFR-targeting drugs
of low general toxicity may enhance the lethal effect of local
irradiation and/or revert tumor resistance [61]. To date,
two different categories of compounds targeting EGFR
have shown antitumor activity: monoclonal antibodies
(mAbs; e.g., cetuximab) and low molecular weight tyrosine
kinase inhibitors (TKIs; e.g., gefitinib), which target extra-
cellular and intracellular domains of the receptor, respec-
tively [87].
Gefitinib has previously been shown to efficiently sup-
press ligand-stimulated endocytosis of EGFR in some cell
types but not in others [88]. Cetuximab was been found to
be internalized as an antibody–receptor complex with
EGFR even though binding of the antibody prevents stim-
ulation of EGFR by endogenous ligands, leading to overall
downregulation of EGFR expression [89]. The effects of
EGFR-directed antineoplastic therapies on its intracellu-
lar trafficking in conjunction with receptor activity have
however not been clearly established and require further
investigation.
Secondary effects of antineoplastic therapies on EGFR
trafficking and activation
Another aspect of the regulation of EGFR trafficking that is
likely to play a key role in cancer development and patient
outcome is the effect of current cancer therapies on EGFR
traffic. Both X-rays and chemotherapy treatments arecapable of generating reactive oxygen species [90] that
lead to the inactivation of redox-sensitive, cysteine-based
protein tyrosine phosphatases [91]. As a result of the
altered equilibrium between basal cellular kinase and
phosphatase activities, EGFR becomes phosphorylated
and the kinase activity of the receptor is stimulated in a
ligand-independent manner [92]. The EGFR itself can also
become directly activated via modification of cysteine resi-
dues located in its active site [93]. This activation is
accompanied by receptor internalization and elicits endo-
cytic trafficking/signaling events that have not been fully
characterized but are either p38- [85,86] or Src-dependent
[94,95], and clathrin- and AP2 adaptor-dependent [96].
One previous study shows that abrogating p38-dependent
EGFR internalization reduces the efficacy of chemotherapy-
induced cell death [86]. This suggests that EGFR-mediated
survival signaling might occur primarily from the plasma
membrane, and therefore ligand-independent EGFR inter-
nalization would enhance the cytotoxic effect of chemother-
apy drugs such as cisplatin. However, in another study
cisplatin was shown to induce both p38-dependent EGFR
internalization and EGFR-dependent PKB/Akt activation,
leading to cisplatin resistance [85]. The biological effects of
this internalization therefore require further clarification to
determine possible synergistic effects of chemoradiotherapy
and EGFR-targeting drugs.
Atypical EGFR trafficking in response to
chemoradiotherapy
Following ionizing radiation treatment, the EGFR has
been proposed to directly enter the nucleus and promote
DNA-PK-dependent non-homologous end-joining double-
strand break DNA repair [97,98]. As described above, the
mechanisms involved in this translocation are controver-
sial, and several molecular pathways have been postulated
(Box 2). Moreover, whether the effect of EGFR on DNA
repair is direct or indirect remains to be established be-
cause such a role could be exerted, without entering the
nucleus, via signaling platforms such as those found on
early endosomes [14].
In addition, mitochondrial translocation of EGFR has
been reported in response to stress and RTK inhibitor
treatments, where it could exert anti-apoptotic effects after
chemotherapy-induced cell death, therefore contributing
to drug resistance [66].
Concluding remarks
Recent advances in our understanding of the molecular
mechanisms regulating EGFR internalization, lysosomal
targeting, and recycling (summarized in Figure 2) have
increased our knowledge of the role that EGFR localiza-
tion plays in the regulation of mitogenic signaling. This
ongoing effort improves our awareness of factors underly-
ing tumorigenesis and may also identify novel therapeutic
targets. A comparatively new and exciting area is the
additional role that EGFR activation and traffic may play
in regulating responses to cancer therapy. Although there
is growing evidence that EGFR signaling plays a role in
cell survival and DNA repair in response to chemora-
diotherapy, there is very little understanding of the role
of internalization and post-endocytic traffic of EGFR in31
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Figure 2. Effectors of ligand-stimulated EGF receptor (EGFR) trafficking pathways. Ligand binding mediates dimerization of EGFRs at the cell-surface, resulting in
autophosphorylation, activation, and internalization. Under normal physiological conditions clathrin-mediated endocytosis (CME) is believed to be the major route of
internalization, but clathrin-independent mechanisms have also been reported under conditions of potent activation [high concentrations of EGF or heparin-binding EGF-
like growth factor (HB-EGF)/betacellulin (BTC)]. Internalized receptors are sorted at the endosome onto the recycling or degradative pathways, with ubiquitination targeting
receptors for lysosomal degradation. Alternative fates reported for endocytosed EGFR, to the nucleus and the mitochondria, are also depicted.
Review Trends in Cell Biology January 2014, Vol. 24, No. 1regulating that response. Determination of the trafficking
pathways followed by stress-activated EGFR and the
molecular mechanisms regulating that traffic will enable
the analysis of the role of EGFR traffic in regulating DNA
repair and cell survival. This will open up the prospect of
development of future treatment strategies, including the
targeting of factors involved in the regulation of cancer
therapy-induced EGFR endocytosis and subsequent intra-
cellular traffic. In combination with current drugs target-
ing the EGFR itself, controlling EGFR traffic could
potentiate therapeutic action against tumors resistant
to conventional chemoradiotherapy.
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